Andrea van Puffelen
The knowledge we gather with WGS can bring us a step closer to our goal to find an effective and suitable treatment for every single patient, not based on ‘one size fits all’, but adjusted to the characteristics of the patient and the tumor.
Back to newsMore news
Broader Testing in AYAs Helps
PhD candidates Jeffrey van Putten and Lina Lankhorst investigated whether AYAs (adolescents and young adults, diagnosed with cancer between the ages of …
Hartwig tools now available as a nextflow nf-core pipeline called oncoanalyser
The University of Melbourne Centre for Cancer Research (UMCCR) Genomics Platform Group, led by Professor Oliver Hofmann, has collaborated with …
Whole Genome Sequencing feasible in clinical practice
Interim WIDE analysis gives researchers more confidence in a positive outcome. On 21 September 2020, Dr. Kim Monkhorst, who is a …
The complete DNA test allows for personalized treatment and so limits the chance of undesirable side effects.